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When (primary) hypothyroidism is diagnosed in a dog, the owners often tell that their dog has not been well for several months or even years. After diagnosis, therapy is started and the dog usually recovers completely. Although the complete recovery makes it very satisfying to treat, the therapy has to be continued lifelong. So it is a challenge to make the therapy that easy, that it will not predominate the lives of both dog and owner. This study will hopefully contribute to that process. 

1.1. Etiology
Hypothyroidism is one of the most common endocrine diseases in dogs (Feldman & Nelson, 2004). The prevalence varies from 0.2% to 0.8% (Panciera, 1994, Ettinger & Feldman, 2005). There are three forms of hypothyroidism: primary hypothyroidism, secondary hypothyroidism and tertiary hypothyroidism. Of these, primary hypothyroidism is the most common form (95%) that mostly results from destruction of the thyroid glands. Secondary hypothyroidism (a deficiency of TSH from the pituitary) and tertiary hypothyroidism (deficiency of TRH from the hypothalamus) are very rare; tertiary hypothyroidism has not even been described in dogs yet. Hypothyroidism can also be congenital or iatrogenic. Dogs are usually between 2 and 6 years old when the clinical manifestations of spontaneous primary hypothyroidism develop. Some breeds are at higher risk, for example Golden retrievers and Dobermans. In this study only dogs with natural occurring primary hypothyroidism were included, thus only (acquired) primary hypothyroidism is described in this paper.

1.2. Pathogenesis
The two main causes for primary hypothyroidism are lymphocytic thyroiditis and idiopathic atrophy of the thyroid glands (Nelson & Couto, 2003). Lymphocytic thyroiditis is responsible for approximately 50% of canine primary hypothyroidism. It is characterized by infiltration of the thyroid gland with macrophages, lymphocytes and plasma cells. The thyroid tissue is destroyed and replaced by fibrous connective tissue. Idiopathic atrophy of the thyroid glands is characterized by loss of thyroid parenchyma without an inflammatory infiltrate.
Primary hypothyroidism can also occur when the thyroids are destroyed by bilateral neoplastic tissue.

1.3. Clinical signs
Primary hypothyroidism may result in a lot of different symptoms and signs, since thyroid hormones influence the function of many organs (Ettinger & Feldman, 2005). The clinical manifestations vary from metabolic symptoms and signs to dermatologic and reproductive symptoms and signs (Nelson & Couto, 2003). Most of the clinical manifestations are described here and classified into groups.

Metabolic





Dogs with primary hypothyroidism often (60%-80%) are presented with problems of the skin or hair coat (Ettinger & Feldman, 2005). These may include alopecia (sometimes with the typical “rat tail”), seborrhoea (sicca or oleosa), pyoderma, dry coat quality, easily epilated hair, and loss of undercoat. Furthermore excessive scaling (dandruff), hyperpigmentation, comedones, hypertrichosis and chronic otitis externa are seen. Myxedema (dermal mucinosis) in the forehead and face of the dogs, caused by the accumulation of mucopolysaccharides in the dermis, is also possible. (Nelson & Couto, 2003; Feldman & Nelson, 2004; Ettinger & Feldman, 2005)

Neuromuscular
Signs referable to the central or peripheral nervous system may occur. This is caused by segmental demyelination and axonopathy induced by the hypothyroidism and accumulation of mucopolysaccharides. Seizures and circling may occur. Weakness, ataxia, unilateral lameness and quadriparesis are examples of peripheral neuropathy. Facial nerve paralysis or vestibular signs are also possible. This can be expressed as head tilt or positional vestibular strabismus. Laryngeal paralysis and megaesophagus have also been reported, but since these signs do not always disappear after L-thyroxin therapy, the relation is still unclear. (Nelson & Couto, 2003; Feldman & Nelson, 2004; Ettinger & Feldman, 2005)

Reproductive
Although there is not much evidence, hypothyroidism can cause prolonged interestrous interval or failure to cycle. For males it is thought that the libido is declined and that testicular atrophy and hypospermia could occur in dogs suffering from hypothyroidism. (Nelson & Couto, 2003; Feldman & Nelson, 2004; Ettinger & Feldman, 2005)

Miscellaneous





Measurement of the plasma total T4 (tT4) concentration can be used in the diagnostic procedures for hypothyroidism. Since most of the tT4 is protein-bound (>99%), a decrease in the concentration does not necessarily mean hypothyroidism. A low plasma tT4 concentration can be due to a nonthyroidal illness (sick euthyroid syndrome), drug administration, or just be normal for that individual. Drugs that influence the thyroid hormone concentration are for example glucocorticoids, sulfonamides, furosemide, propanolol, phenobarbital, progestagens, phenylbutazone, methimazole and carprofen (Daminet et al., 2003).When the dog has a nonthyroidal illness, the plasma thyroid hormone concentration is often decreased. This can be caused for example by a change in hormone binding to serum carrier proteins or a decreased synthesis of TSH or thyroid hormones.
Free T4 can also be measured. This is unbound T4, biologically active and responsible for the main feedback on the pituitary. So since the free T4 is not protein-bound, these concentrations generally are not influenced by drugs or nonthyroidal illness. fT4 is usually measured by the equilibrium dialysis, but this is an expensive method.
Furthermore, serum T3, free T3 and reverse T3 can be measured. This is not recommended because most of the T3 and rT3 is not formed in the thyroid, but is deiodinated out of T4 outside the thyroid gland. The T4 on the other hand is always formed in the thyroid gland and is thus a more informative measurement. (Nelson & Couto, 2003; Feldman & Nelson, 2004; Ettinger & Feldman, 2005)

Thyroid stimulating hormone (TSH) and Thyrotropin (TRH)
The plasma TSH concentration can be measured in combination with tT4 or fT4 measurement. The measurement of the plasma TSH concentration alone does not say much (Ramsey et al., 1997). However, when a high plasma TSH concentration in combination with a low plasma tT4 or fT4 concentration is found and the clinical manifestations fit, this strongly supports the diagnosis of primary hypothyroidism.
A TSH or TRH stimulation test is also a possibility to diagnose hypothyroidism. The tests show how the thyroid gland responds to exogenous TSH or TRH administration. (Nelson & Couto, 2003; Feldman & Nelson, 2004; Ettinger & Feldman, 2005) Of these two tests, the TSH stimulation test is the most useful in differentiating between primary hypothyroidism and sick euthyroid syndrome (Frank, 1996; Diaz Espineira et al., 2007b). 

Scintigraphy
Scintigraphy of the thyroid gland shows to what extend the thyroid gland is able to take up 99mTcO4-. This is an indicator of the ability of the uptake of iodide by the thyroid gland, and shows if there is any functional thyroid tissue left. This is a good procedure in the diagnosis of primary hypothyroidism (Diaz Espineira et al., 2007b).










The prognosis for dogs suffering from primary hypothyroidism treated with L-T4 is usually excellent.


1.7. Aim of the study

The main goal of the study is to answer the following question:
Is a liquid formulation of L-thyroxine, administered orally once daily in a starting dosage of 20 µg/kg body weight, effective and safe for treatment of dogs with primary hypothyroidism?
This will be evaluated by answering two other questions:
-	Do the clinical symptoms and signs improve sufficient in 4 weeks of treatment?
-	Do the pharmacokinetics of total thyroxine support the effectiveness of this treatment?

The pharmacokinetics have already been evaluated in healthy dogs (Le Traon et al. 2008). The latter study showed that one single dose of an oral solution of levothyroxine is as effective as the tablet formulation administered in the same dosage at 12-h intervals, since 50% less levothyroxine is absorbed when it is given in a tablet formulation. Furthermore the study showed that there is a high inter-individual variation in the absorption of thyroxine after oral administration. So may be it will be necessary to adjust the levothyroxine dose individually for all patients to achieve therapeutic concentrations of tT4. Although the results of this study support the hypothesis that once daily administration of the liquid formulation of L-thyroxine might be sufficient to control the disease, the study was performed in euthyroid dogs. This makes it hard to say to what extend the endogenous production of T4 interfered with the L-thyroxine administered orally and how that affected the evaluation of the pharmacokinetic parameters.

The administration of the liquid formulation of L-thyroxine once daily has recently been clinically evaluated and reported (Le Traon et al. 2009). This study showed that the starting dosage of 0.02 mg/kg body weight once daily was suitable for 79% of the dogs. In these dogs, hypothyroidism was solely diagnosed based upon a low plasma fT4 concentration and an elevated TSH concentration. The pharmacokinetic profile was not determined in this study.









Twelve dogs diagnosed with primary hypothyroidism were selected. There were no restrictions regarding sex, age or body weight. The dogs were housed at their own home and there were no requirements regarding the nature of their diet. Two different types of dogs with primary hypothyroidism could enter the study, namely:
-		Dogs with newly diagnosed hypothyroidism that have not been supplemented with L-thyroxine prior to inclusion in the present study. 
-		Dogs with properly diagnosed hypothyroidism and treated with L-thyroxine (irrespective of the form) prior to inclusion.
For the dogs to be included a definitive diagnosis of primary hypothyroidism had to be made. This was done as follows:
- Newly diagnosed dogs:
Dogs were pre-included based on clinical signs suggestive of hypothyroidism. The diagnosis then was confirmed by the following laboratory investigations:
	Basal total thyroxine (tT4) concentration < 10 nmol/l, preferably combined with a basal thyroid stimulating hormone (TSH) concentration > 0.6 µg/l.
	Results of thyroid stimulating hormone (TSH) stimulation test confirming thyroid insufficiency, i.e. that the increase in tT4 concentration between pre- and post-injection time was less than 5 nmol/l. The TSH stimulation test was performed as follows: rhTSH was administered intravenously (100 μg rh TSH for dogs with a body weight < 30 kg; 200 μg rh TSH for dogs with a body weight ≥ 30 kg) and tT4 concentration was determined at 4 hours post-injection (for this purpose, approximately 1 ml blood was collected in a heparinized tube) (Daminet et al., 2007) (De Roover et al., 2006) (Sauve et al., 2000)
	Thyroid scintigraphy showing a non- or poorly functioning thyroid gland. This test was performed as follows: the dog was administered 99mTcO4-  intravenously (90 MBq for a dog with a body weight < 15 kg, and 135 MBq for a dog with a body weight between 15 and 40 kg). Then about 45 minutes after 99mTcO4- injection, the uptake of the radiopharmaceutical from the thyroid area and from the salivary glands were evaluated and compared.
- Already treated dogs:
	Historical data fulfilling the inclusion criteria listed above should be available,
	The daily dose of L-thyroxine at inclusion should be around 20 μg/kg body weight, irrespective of the frequency of the administration (once or twice daily).

- For determination of basal tT4 (< 10 nmol/l) and TSH (>0.6 μg/l), a blood sample of approximately 1.5 ml (heparinized tube) was taken at the inclusion visit (Visit n°1) and after 4 ± 1 weeks of treatment (Visit n°2).
- For storage and potential further analysis, a blood sample of approximately 8 ml was collected, divided over 3-4 ml EDTA, 3-4 ml heparinized, and 1 ml sodiumfluoride. This was also done at visit n°1 and visit n°2.
- Of each case, the complete history was recorded, including previous drug therapy and possible (previous) diseases. The owners were asked to fill in a classification schedule with clinical symptoms at visit nº1 and at visit nº2. 
- Furthermore, a thorough clinical examination was done at visit nº1 and visit nº2.




Dogs exhibiting one or more of the following pathologies were excluded from the study:
	Concomitant endocrine disorder (such as insulin-dependent diabetes mellitus, hyperadrenocorticism, adrenocortical insufficiency).
	Dogs with chronic renal failure.
	Dogs with chronic hepatic failure.
	Pregnant or lactating bitches.
In case of any obvious pathology known to decrease thyroid hormone levels, the dog was not eligible for inclusion.

For newly diagnosed dogs, the following cases were excluded:
	Dogs which had received any thyroid hormone supplementation within 8 weeks of inclusion in the study. 
	Dogs which had received antithyroid drugs (e.g. propylthiouracyl, methimazole, carbimazole) within 6 weeks of inclusion of the study.




At visit n°1, the owner of the dogs was informed of the relevant details of the study. The owner confirmed his/her agreement to participate to the study by signing and dating, together with the veterinary investigator, the “Owners Informed Consent”.

Treatment schedule:
When the dogs were selected and fulfilled all the inclusion criteria, they were administered L-thyroxine sodium solution (Leventa®, 1 mg/ml, Intervet International B.V.) orally at a dose rate of 20 μg/kg body weight once daily, preferably in the morning to fit with sampling schedule (Le Traon et al. 2008). The dogs were fed immediately after treatment administration every day. Leventa® was administered once daily during 4 ± 1 consecutive weeks until pharmacokinetic evaluation (visit nº2). 
Leventa® is a solution for oral use, containing 1 mg/mL of L-T4. The Leventa® is supplied in a 30 ml bottle with a child-resistant screw cap, provided with a dosing syringe allowing increments of 0.05 ml to be administered. The bottles were stored in the refrigerator at the owners place and were returned when empty or when the bottle had been open for 6 months. The Leventa® was supplied to the pharmacy of the Faculty of Veterinary Medicine, Utrecht, The Netherlands, by Intervet Belgium, Bedrijvenlaan 7, 2800 Mechelen, Belgium.
During the 4 ± 1 weeks treatment, the owners were asked to record obvious changes seen in the dog, side effects, events or symptoms.

Sampling schedule for pharmacokinetic evaluation (visit nº2):
The pharmacokinetic profile of tT4 was determined after 4 ± 1 weeks of once daily treatment of Leventa®. On the day of the pharmacokinetic evaluation, the dogs had been fasted overnight at arrival to the study site. 
As mentioned before, the dogs were weighed and photographs were taken. A thorough clinical examination was done and some blood (T=0) was taken (1.5 ml into a heparinized tube for determination of basal tT4 and TSH concentrations) and stored for further analysis (3-4 ml into an EDTA tube, 3-4 ml into a heparinized tube, 1 ml into a sodiumfluoride tube). 
The blood sampling for determination of tT4 (each time approximately 1 ml into a heparinized tube) was performed just before treatment (T=0) and over 34 hours at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24 and 34 hours after oral administration of Leventa®. The dogs were fed immediately after treatment administration. The next dose of Leventa® was postponed until after the 34 h sampling point.
The nature of the food was standardized as much as possible to limit variability in the absorption of L-thyroxine between dogs. Feeding on the day of pharmacokinetic evaluation was documented (feeding time, food type and amount).





Plasma samples were analyzed at Utrecht University. Immediately following collection, blood samples were centrifuged, obtained plasma transferred into dry tubes stored at about -20°C until subsequent analysis.
The method used to evaluate tT4 and TSH concentrations in plasma samples are described below:
	plasma tT4 concentrations were determined by a commercial homologous solid-phase, chemiluminescent enzyme immunoassay (Immulite canine total T4®) supplied by Diagnostic Products Corporation (DPC, Los Angeles, CA, USA), and used in accordance with the instructions of the manufacturer.
	plasma TSH concentrations were determined by a commercial homologous solid-phase, two-sites chemiluminescent enzyme immunometric assay (Immulite canine TSH®) supplied by DPC (Los Angeles, CA, USA), and used in accordance with the instructions of the manufacturer.

Evaluation of results:
The plasma concentration-time profile of tT4 from each individual dog was evaluated according to standard pharmacokinetic methods. Pharmacokinetic parameters were calculated from observed post-treatment tT4 concentrations using standard non-compartmental methods. tT4 concentrations were not corrected by pre-treatment value.
The following parameters were determined:
Cmax (nmoL/L)	:	maximal plasma concentration.
tmax (h)			:	time to reach Cmax (h).
Furthermore for each patient it was determined whether the tT4 concentration was within the reference range over 24 hours.












Twelfe dogs were initially selected of which 2 were excluded. One because thyroid scintigraphy showed too much uptake in the thyroid gland tissue and the other had a too high response on TSH stimulation. So, eventually 10 dogs were included for the study. Nine dogs were newly diagnosed and one dog was included that had been diagnosed with primary hypothyroidism before and had already started L-thyroxine therapy. The mean age of the 10 dogs prior to this study was 6.4 years (S.E.M. 0.75) with a range of 4 to 11 years. Four dogs were castrated females, 1 a non-castrated female, 3 castrated males, and 2 non-castrated males. 
All the information about the patients is documented and can be found in the patient files in the Insets.

Prior to the study the dogs were selected upon a low tT4 concentration (< 10 nmol/l) and preferably a high TSH concentration (> 0.6 µg/l). Table 1 shows the tT4 and TSH concentration in the plasma of the dogs at the start of the study.

Table 1. tT4 and TSH concentration at visit nº 1.
















Reference values for TSH and tT4:
- TSH: < 0.60 µg/l
- tT4: 19-46 nmol/l
3.1. Anamnesis















	Parameter	Mean at visit nº1	SEM	Mean at visit nº2	SEM	Significance(P)	Number of dogs (N)

















3.3.1. Thyroid hormone (tT4)

At visit nº2 a pharmacokinetic profile of tT4 was determined after 4 ± 1 weeks of once daily treatment of Leventa®.  The profiles of the dogs are shown in table 4.

Table 4. Plasma tT4 concentrations (nmol/l) at different sample points (T = x hours) post-treatment.












































3.3.2. Thyroid stimulating hormone (TSH)

Plasma TSH concentrations were determined before and after 4±1 weeks of treatment with 20 µg Leventa/kg body weight, administered orally once daily. These are shown in Table 7.

Table 7. Plasma TSH concentration (µg/l) before and after 4±1 weeks of treatment with 20 µg Leventa/kg body weight, administered orally once daily.



































Of each dog photographs were taken at visit nº1 and at visit n°2. The photographs can be found in the separate patient files.

3.6. Deviations of protocol

There was one deviation of protocol during the study. The owner of dog Lucky forgot to administer the Leventa® once in the week prior to visit n°2. 

3.7. Adjustments of the dosage regimen

After visit nº2, 6 of the 10 dogs were advised to change the dosage regimen. Four dogs remained on the same dosage. This was based on the clinical improvements and the tT4 and TSH concentrations at visit nº2. Table 9 shows the adjustments of dosage regimen for each dog.

Table 9. Adjustments of dosage regimen at visit nº2 (i.e. after 4±1 weeks of treatment)

Dog	Adjustment
Astra	Dosage stayed the same, 0.3 ml once daily
Boomer	Dosage stayed the same, 0.4 ml once daily
Tibbe	Dosage increased, from 0.7 ml to 0.8 ml once daily
Bella	Dosage increased, from 0.8 to 0.9 ml once daily
Govert	Dosage increased, from 0.5 to 0.6 ml once daily
Brutus	Dosage increased, from 1.2 ml to 1.3 ml once daily
Lucky	Dosage stayed the same, 0.15 ml once daily
Harm	Dosage stayed the same, 0.6 ml once daily
Floor	Dosage increased, from 0.4 ml once daily to 0.25 ml twice daily






In this study only dogs that had been diagnosed with severe primary hypothyroidism could be included. All the dogs had clinical manifestations that suggested hypothyroidism, such as exercise intolerance, lethargy, cold intolerance, and weight gain. Furthermore most dogs had dermatologic problems as excessive scaling, alopecia, and hair loss. One dog (Floor, n° 11) had large interdental spaces and the gingiva was also a bit swollen. This might be the result of an elevated growth hormone secretion due to primary hypothyroidism (Lee et al., 2001, Diaz-Espineira et al., 2007a).
All dogs had a plasma tT4 concentration < 2 nmol/l and a plasma TSH concentration > 0.60 µg/l (except for one dog (Astra) that had a plasma TSH concentration of 0.14 µg/l). The combination of a low plasma tT4 concentration and a high plasma TSH concentration strongly suggests hypothyroidism (Panciera, 1999; Dixon et al., 1999). Since a quarter to a third of dogs with primary hypothyroidism have plasma TSH concentrations within the reference range, other diagnostic procedures are recommended to confirm the diagnosis (Scott-Moncrieff et al., 1998; Peterson et al., 1997). Good diagnostic procedures are scintigraphy and a TSH stimulation test using rhTSH (Diaz-Espineira et al., 2007; Sauvé et al., 2000; Daminet et al., 2007). In this study both procedures were performed and only when the scintigraphy showed a non- to poorly functioning thyroid gland, and the tT4post-rh TSH - tT4basal < 5 nmol/L , the dog was included for the study.

A dose rate of 20 µg L-thyroxine/kg body weight once daily was used for the therapy. The safety and efficacy of this particular L-thyroxine solution has been studied before. (Mooney et al., 2006) As well as in our project, that study showed that all the dogs responded to the treatment and that the first signs that disappeared, were the metabolic signs. 

During the therapy, the dogs had to be fed immediately after administration of L-thyroxine. Then the bioavailability of the Leventa® would not fluctuate a lot and it would be the same for all dogs. (Le Traon et al., 2008) 
At visit nº2, not all the dogs were fed with the same amount of food. This was because the food that the dogs have at their own place was given. Some owners forgot their own food and then the dogs were fed with the food supplied in the clinic. Sometimes it was hard to feed the dogs immediately after treatment in the clinic, since some dogs did not want to eat at all. It was strived for to give them some food within 10 minutes after treatment.

At visit n°2, the clinical improvements were evaluated and the plasma TSH and tT4 concentrations were determined. The most obvious signs that had improved over 4±1 weeks of treatment were the increase in activity, exercise tolerance, and weight loss. Furthermore the tragic facial expression (myxedema) diminished. Although some dermatologic signs got worse during those weeks for some dogs (scales, hair loss), alopecia and dry coat quality declined over 4±1 weeks of treatment. The coat density got better during those weeks of therapy. It is reported that dermatologic signs usually take a lot longer to resolve (Panciera, 1997). 

Concerning the pharmacokinetics, the plasma tT4 concentration showed a significant increase after 4±1 weeks of treatment. The plasma TSH concentration showed a significant decrease after 4±1 weeks of treatment. The mean maximum plasma concentration of tT4 was 48 nmol/l with a range of 22 to 64 nmol/l. This range is quite wide, which could be due to the individual variability in pharmacokinetic parameters (Nachreiner et al., 1993; Le Traon et al., 2008). The time to reach this mean Cmax was 5 hrs after administration. The mean maximum plasma concentration of 48 nmol/l is just above the reference range (i.e. 19-46 nmol/l). Over 24 hrs, 7 dogs had a plasma tT4 concentration within reference values (19-46 nmol/l) and 3 dogs did not. Out of 7 dogs, one dog had a plasma TSH concentration that was not within the reference values ( < 0.60 µg/l) after 4±1 weeks of treatment.

For most dogs, once daily administration of L-thyroxine seemed appropriate. Seven of 10 dogs had a plasma tT4 concentration that was within the reference range over the first 24 hours. Nine of 10 dogs reached plasma tT4 concentrations in the upper half of or above the reference range in the 34 hours post treatment. This suggests that once daily administration is sufficient to treat primary hypothyroidism. This is supported by the findings in other studies. One study has shown earlier that a starting dosage of 20 µg L-T4/kg BW once daily is suitable for 79 % of dogs. However the primary hypothyroidism had not been diagnosed as strong as in this study, so endogenous production of T4 could have played a role. Furthermore after 4 weeks of treatment, the tT4 was only monitored at one moment, namely 4-6 hours post treatment. In this study, a pharmacokinetic profile over 34 hours post treatment was made. (Le Traon et al., 2009)

Concerning the dosage regimen, each dog was advised individually after visit n°2. When the TSH concentration was < 0.60 µg/l, the tT4 within reference values over 24 hrs and the dog had made sufficient clinical progress, the dose rate did not have to be changed. Although it is usually advised to measure the plasma TSH and tT4 concentration 4-6 hours post treatment (the serum tT4 concentration should fall in the upper half of the reference range, or above), this study offered the opportunity to look at the tT4 concentration from 0 to 34 hrs post treatment (Mooney et al., 2006; www.leventa.com (​http:​/​​/​www.leventa.com​)). The monitoring of the treatment was far more accurate this way.

Still, one can question if the dose rate of 20 µg L-T4/kg BW administered once daily is sufficient for all dogs (Mooney et al., 2006; Le Traon et al., 2008; Le Traon et al., 2009; Nachreiner et al., 1993). In our study, 6 of 10 dogs needed a dosage increment after 4±1 weeks of treatment. Moreover for one dog (Floor) once daily administration did not seem to be sufficient. This dog had a plasma tT4 concentration that was almost immeasurable low 24 hours after Leventa administration. This dog was advised to be treated with L-T4 twice daily instead of once daily. This can be due to the high inter-individual variability between the dogs concerning pharmacokinetic parameters (Nachreiner et al., 1993; Le Traon et al., 2008). Another dog (Luna) had a good clinical response to the therapy after 4±1 week of treatment and had good tT4 concentrations over 34 hours. Still the TSH concentration was quite high (>0.60 µg/l). This could be due to a TSH pulse, so the TSH concentration was measured again after 24 hours (Kooistra et al.,1999). Again the TSH concentration was quite high (>0.60 µg/l). This dog was then advised to increase the dosage regimen.

So, for most dogs, once daily oral administration of 20 mg L-tT4/kg BW, seems to be sufficient to achieve clinical improvements and therapeutic acceptable plasma tT4 concentrations. Still, this should be monitored individually and if needed adjusted for each dog.
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